Satellite Symposia

Satellite symposia descriptions will be posted as they are confirmed. Please visit this page regularly for updated information.  

Thursday, April 2

Satellite Symposium - Purdue Pharma (16:45 - 18:15)

Chemotherapy-Induced Nausea and Vomiting: Contemporary Challenges of Management

Learning Objectives:

  1. Understanding basic pathophysiology of CINV;
  2. Review the key updates from current guidelines; and
  3. Highlight the newest developments regarding contemporary management of CINV.

Satellite Symposium - Janssen (18:30 - 20:00)

Improving Long-term Management of Patients with CLL & Multiple Myeloma

Learning Objectives:

  1. To discuss key considerations in managing patients on long-term therapies and the role of the pharmacist in order to support better treatment outcomes; 
  2. To explore opportunities to improve the patient experience on continuous treatments for CLL and how to avoid unnecessary treatment discontinuations; and
  3. To share best practices related to the administration and management of novel treatments for Multiple Myeloma in order to reduce patient and institutional burden.

Friday, April 3

Satellite Symposium - Pfizer Oncology (07:00 - 08:15)

Top Insights on Creating a Sustainable Oncology Landscape; It’s Biosimple

Learning Objectives:

  1.  Learn from key pharmacy experts on their challenges and lessons learned to implementing oncology biosimilars in their Cancer Center;
  2.  Uncover next steps for oncology biosimilars and how to best prepare; and
  3.  Discuss your role as pharmacist in supporting and maintaining a sustainable oncology biosimilars environment in the future.   
     

Satellite Symposium - Pfizer Canada (8:30 - 9:45)

Treatment of Iron Deficiency: A New Paradigm

Learning Objectives:

  1. Describe the different IV iron preparations available in Canada;
  2. Understand the key clinical trials evaluating iron isomaltoside1000 (Monoferric®);
  3. Have a practical approach to anaphylaxis and hypersensitivity reactions to IV iron; and
  4. Better understand how to implement Iron isomaltoside protocol within institutions/hospitals and how to overcome challenges.

Satellite Symposium - AbbVie (10:00 - 11:15)

Hot Topics in CLL: Focusing on the Evolving Patient Journey

Learning Objectives:

  1. Recognize the available treatment options for CLL;
  2. Consider the patient’s personal goals in treatment selection;
  3. Integrate best practices for treatment initiation within their own practice environment;
  4. Effectively manage common treatment-related side effects.
     

Satellite Symposium - Apobiologix (11:30 - 12:45)

Embracing Change – Ushering in a New Era of Biosimilar Treatment Options

The biosimilars landscape is evolving rapidly following the launch of biosimilar versions of leading biological medicines globally. In Canada, there are multiple therapeutic biosimilar agents on the horizon for each blockbuster monoclonal antibody currently used in oncology and decisions will have to be made between the various agents. Not only will existing health policies need to be tailored for these therapeutic biosimilars to ensure sustainability and a favorable budget impact, but there will also be practical aspects that providers and institutions will face requiring thoughtful consideration. In this symposium, we will explore and discuss practical considerations and challenges faced, from decision making to institutional process management; and best practices for the effective adoption and implementation of therapeutic biosimilars in Canada.

Learning Objectives:

  1. Share lessons learned in adopting therapeutic biosimilars from a European perspective;
  2. Explore and continue to discuss health policies that need to be tailored for therapeutic biosimilars to ensure sustainability and a favorable budget impact;
  3. Discuss practical considerations and challenges that oncology pharmacists face when choosing a biosimilar; and
  4. Share best practices for effective adoption and implementation of therapeutic biosimilars within a Canadian oncology center.

Satellite Symposium - Pfizer Oncology (13:00 - 14:15)

The Pharmacist Experience on Metastatic Breast Cancer & Case Studies

This program is designed to gain insights on the managing metastatic breast cancer patients through patient case discussions. In this symposium, meaningful education in support of clinical and pharmacists’ perspectives will be discussed featuring the utmost clinical evidence in metastatic breast cancer across various patient sub-groups and its optimal management. 

Learning Objectives:

  1. Build knowledge related to the clinical presentation and understand patient management implications of mBC patients;
  2. Discuss case profiles of HR+ HER2- mBC patients;
  3. Share perspective on safety and tolerability of CDK4/6 inhibitors;
  4. Provide practical tips for adherence and patient education; and 
  5. Review scientific data supporting the introduction of palbociclib tablet formulation.

Satellite Symposium - Teva (14:30 - 15:45)

2020 Vision: Integration of Biosimilars in Provincial Programs

With the introduction of therapeutic biosimilars in the field of oncology, pharmacists have important roles to play in providing education and in the logistical implementation of integrating these therapies into practice. Through this talk show-style format, a panel of Canadian experts will review recommendations of Canadian agencies with regards to biosimilars, and share their experiences with integrating biosimilars into practice in order to identify key learnings and challenges. This symposium will help participants to assess where we currently stand in terms of implementing recommendations for the use of biosimilars in oncology and to determine the next steps for achieving this vision.  

Satellite Symposium - Kite (Gilead) (16:00 - 17:15)

The Role of Pharmacy in CAR T-Cell Therapy for Lymphoma

Celina Dara, Clinical Site Leader – Pharmacy Department, Princess Margaret Cancer Centre, Toronto, ON

  1. Provide a background of the unmet need in Large B-Cell Lymphoma (LBCL);
  2. Review Chimeric Antigen Receptor (CAR) T-Cell Therapy, including pivotal trials for LBCL;
  3. Review the role of the Pharmacist in Authorized Treatment Centres, including:
    1. patient management for lymphodepletion, infusion and post-infusion stages;
    2. the role of Pharmacy in multi-disciplinary CAR T care teams;
    3. CAR T patient management intervention strategies and algorithms; and
  4. Review long term patient follow-up in the community setting from a pharmacist perspective.

Saturday, April 4

Satellite Symposium - BD (7:00 - 8:30)

Optimizing Oncology Workflow and Preparation 

This session will describe the implementation and lessons learned for drug vial optimization and IV workflow. This presentation will review current available processes and technologies that can be implemented to potentially decrease drug waste and bring in workflow changes that facilitate the safe and efficient compounding and administration of hazardous drugs. In order to meet NAPRA standards, both IV workflow and closed-system transfer devices will be critical for hospital pharmacies. A review of a large U.S. institution and a Canadian hospital for both closed system transfer devices and IV workflow will be detailed. 

Sunday, April 5

Satellite Symposium - Hoffman-La Roche (7:00 - 8:30)     

The Changing Treatment Landscape in Advanced Lung Cancer: Progress Made and Challenges to Address in 2020

Learning Objectives:

  1. Discuss the impact of new treatment options for advanced lung cancer;
  2. Identify how molecular markers guide clinical decisions for patients with advanced NSCLC; and
  3. Review individualized treatment strategies for patients with advanced NSCLC and extensive stage SCLC.

Satellite Symposium - Hoffman-La Roche (12:30 - 14:00)

Findings from the SubCutaneous Benefit Analysis (SCuBA): A Discussion across Canadian Institutions

Frontline treatment for diffuse large B-cell lymphoma and follicular lymphoma in Canada involves intravenous (IV) infusion of rituximab. Recently, its subcutaneous (SC) formulation was approved by Health Canada for use in both malignancies. Featured sessions will bring together a unique panel of pharmacists from across Canada to share perspectives on institutional, health care professional, and patient impact resulting from administration differences between SC and IV drug formulations. Through an active panel discussion, they will review implementation experiences of rituximab SC to understand successes and challenges. Furthermore, they will discuss the integration of SC formulations, reference biologics and biosimilars, within cancer centres.

Learning Objectives:

  1. Share perspectives on institutional, health care professional (HCP), and patient impact resulting from administration differences between SC and IV drug formulations;
  2. Compare the implementation experience of rituximab SC to understand successes and challenges; and
  3. Discuss the integration of SC formulations, reference biologics and biosimilars, within cancer centres from a pharmacist perspective.